



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
ANDREW J. DANNENBERG, et al.)
Patent Application No. 10/614,795)
Filed: July 9, 2003)
For: MULTI-FUNCTIONAL COX-2)
INHIBITORS)

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Documents being brought to the attention of the PTO are listed in the attached PTO-1449 (two pages) and one copy of each listed document is enclosed.

Please consider the enclosed documents and initial on the PTO-1449, opposite each listing, to make of record such consideration and transmit a copy of the initialed PTO-1449 to the undersigned.

Respectfully submitted,

By: 
Eric S. Spector
Reg. No. 22,495

JONES, TULLAR & COOPER, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703-415-1500

Case: CRF D-2756 NP

Date: October 7, 2003

OCT 07 2003

ATTY. DOCKET NO.
CRF D-2756 NP

APPL'N NO. 10/614,795

APPLICANT: ANDREW J. DANNENBERG et al

FILING DATE July 9, 2003

GROUP:

REFERENCES DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	6,200,760	03/01	Dannenberg et al	435	6	
	AB	6,291,496	09/01	Dannenberg et al	514	376	
	AC	6,403,630	06/02	Dannenberg et al	514	406	
	AD	6,486,203	11/02	Dannenberg	514	473	
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATED Y N
	AL	WO 99/30721	06/99	WIPO			
	AM	WO 02/089790	11/02	WIPO			
	AN	WO 00/13685	03/00	WIPO			
	AO						
	AP						

OTHER ART (including Author, Title, Pertinent Pages, etc.)

	AR	1	Behrens, J., Annals New York Academy of Sciences 910, pages 21-35 (2000)
		2	Ortega, S. et al, Biochimica et Biophysica Acta 1602, 73-87 (2002)
	AS	1	Ramos-Gomez, M. et al, PNAS, 98(6), 3410-3415 (3/2001)
		2	Schoonjans, K., et al, J. Biol. Chem. 270 (33), 19269-19276 (08/95)
	AT	1	Subbaramaiah, K., et al, J. Biol Chem. 276(15) 12440-12448 (4/01)
		2	Yamada, K.M., et al, Journal of Cell Science 114, 2375-2382 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OCT 01 2003

ATTY. DOCKET NO.
CRF D-2756 NP

APPL'N NO. 10/614,795

APPLICANT: Andrew J. Dannenberg, et al

FILING DATE July 9, 2003

GROUP:

REFERENCE & PRIORITY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATED Y N
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER ART (including Author, Title, Pertinent Pages, etc.)

AR	3	Barker, N., et al, Pub. Med Abstract of Adv Cancer Res 77, 1-24 (2000)
	4	Winslow, R. "Arthritis Drug Celebrex Shown Promise as Cancer Weapon", The Wall Street Journal, B1 (5/22/02)
AS	3	Cayman Chemical Company Catalog, 10/10/01, pages for 70272, 70274, 70278, 70655
	4	Calbiochem Catalog, 8/23/01, page for 565605
AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement - Section 9 PTO-1449 (Page 2 of 2)